VBEF Healthcare’s Post

RheumaTrace™ is a breakthrough biomarker panel for researching rheumatic diseases, backed by three decades of research and over 200 peer-reviewed publications. This video shows how our rheumatology biomarkers can be applied in a clinical setting. The panel comprises seven distinct biomarkers, carefully selected to encompass the intricacies of connective tissue degradation and immune cell dynamics. Together, these biomarkers offer researchers and drug developers invaluable insights into disease activity, the trajectory of disease progression, and the efficacy of therapeutic interventions. RheumaTrace™ is suitable for investigating drug response, dose-finding, efficacy prediction, targeted patient identification and much more. If you wish to learn more, please reach out to Anne C. Bay-Jensen or Mayuur Bajaj.   #RheumaTrace #Rheumatology #RheumatoidArthritis #PrecisionMedicine #DrugDevelopment

AIM (Apoptosis Inhibitor of Macrophage) is suggested to associate with various diseases such as metabolic syndrome that is originated lifestyle diseases (arteriosclerosis and diabetes), fatty liver, acute kidney injuries and liver cancer. AIM binds to pentamer IgM in blood and IBL's ELISA can measure Total AIM since the antibody used in this kit can detect IgM binding form, too. Human AIM/CD5L Assay Kit (#27265) https://lnkd.in/dt49_9f Learn more: https://lnkd.in/gGHiaE4 #Antibodies #ELISA #Biomarkers #Immunoassay #Clinicaltrials #Clinicalresearch #Apoptosis #Macrophage #Metabolicsyndrome #Kidneyinjuries #Fattyliver #Livercancer #Cancer #Diabetes #Triglyceride

#Review Current Status and Future Perspectives of Lactate Dehydrogenase Detection and Medical Implications: A Review by Yangzhe Zhou, Min Qi and Minghui Yang https://lnkd.in/dEd3RuA2   #MDPI #fluorescence #tumor #glucose #biosensors #sensors #openaccess   #Abstract The demand for glucose uptake and the accompanying enhanced glycolytic energy metabolism is one of the most important features of cancer cells. Unlike the aerobic metabolic pathway in normal cells, the large amount of pyruvate produced by the dramatic increase of glycolysis in cancer cells needs to be converted to lactate in the cytoplasm, which cannot be done without a large amount of lactate dehydrogenase (LDH). This explains why elevated serum LDH concentrations are usually seen in cancer patient populations. LDH not only correlates with clinical prognostic survival indicators, but also guides subsequent drug therapy. Besides their role in cancers, LDH is also a biomarker for malaria and other diseases. Therefore, it is urgent to develop methods for sensitive and convenient LDH detection. Here, this review systematically summarizes the clinical impact of lactate dehydrogenase detection and principles for LDH detection. The advantages as well as limitations of different detection methods and the future trends for LDH detection were also discussed.

Goodbye inhalers? Chinese trial offers potential one-shot asthma cure Asthma, a pervasive respiratory disease, affects over 300 million people globally and results in more than 250,000 deaths annually. This development offers a potential one-time solution for a condition that currently requires lifelong management. Chinese scientists have unveiled a pioneering cell therapy that promises long-term relief for asthma sufferers with a single shot. This new method, based on advanced techniques usually used for cancer, has shown great promise in animals. It brings hope to millions worldwide who struggle with this chronic respiratory condition. Traditional treatments, such as inhalers and antibody injections, require continuous, lifelong administration without offering a definitive cure. However, this new treatment, which uses CAR-T (chimeric antigen receptor T-cell therapy), aims to change that approach.

Druggability, molecular targets, and nanocarrier delivery of natural triterpenoid celastrol against chronic diseases https://lnkd.in/empjwCmJ #cancer #Celastrol #diabetes #inflammation #neurodegeneration #obesity

Advancing Therapies for Fibrotic Diseases and Anti-Aging with IL-11 Antibodies IL-11 plays a crucial role in fibrogenesis, organ dysfunction, and inflammation, making it a promising therapeutic target for conditions like idiopathic pulmonary fibrosis (IPF), liver fibrosis, and non-alcoholic steatohepatitis (NASH). Recent studies even suggest that IL-11 inhibition can extend the lifespan of aged mice. Therefore, anti-IL-11 therapy holds potential as a dual-purpose treatment aimed at both disease mitigation and delaying aging. At Biocytogen, we've developed fully human IL-11 antagonist antibodies using our RenMice platform, demonstrating cross-species affinity and superior blocking activity. In addition to IL-11, our portfolio includes antibodies targeting key markers in inflammatory, autoimmune, and metabolic diseases. Explore partnership opportunities with Biocytogen to bring innovative treatments to life. #Biocytogen #IL11 #Fibrosis #AntiAging #Biotech #DrugDevelopment #Innovation #Partnerships

RheumaTrace™ is a carefully selected biomarker panel for rheumatic diseases. These biomarkers delve deep into connective tissue degradation and immune cell dynamics, offering insights to researchers and drug developers. They can pinpoint disease pathways and help determine optimal drug dosages for effective treatment. 🧬 Key Features of RheumaTrace™: ✅ Three decades of research-backed development ✅ Seven distinct biomarkers for precise analysis ✅ Rapid response to drug interventions within days and weeks ✅ Ideal for dose-finding and efficacy prediction in trials ✅ Useful for comparing drug responses in head-to-head studies 💡Interested? Learn more at https://lnkd.in/ek-Pqc3N or reach out to Anne C. Bay-Jensen and Mayuur Bajaj. #RheumaTrace #Rheumatology #RheumatoidArthritis #PrecisionMedicine #DrugDevelopment

⭕A very uncommon instance of secondary malignancy in a patient treated with CAR T-cell therapy is explained by new study. ⭕The term "CAR" refers to the chimeric antigen receptor, which is made up of single-chain variable fragments (scFv) and intracellular signalling domains of T cells. #CAR-T cell therapy #cancer #monoclonalantibodies #disease #research ⭕Radiation therapy carries the danger of secondary malignancies.Several published studies have demonstrated that the incidence of secondary malignancies is only slightly increased by proton therapy when compared to x-rays. ⭕Although 4% to 16% of patients who receive chemotherapy and radiation therapy are known to develop secondary cancers, the Food and Drug Administration's (FDA) Adverse Events Reporting System database only has approximately 20 reports of T-cell malignancy following CAR T therapy. ⭕A/C to research, For almost all CAR-T recipients, the potentially life-saving benefit of CAR-T is likely to outweigh this risk. https://www.apivirine.com/ #plantbasedsciences #plantbadeddiets #plantbasedliving #plantbasedathlete #plantpower #pbsi #pbsicanada #pbsiindia #pbsiafrica #pbsijamaica #pbsicoastarica #apivirine #healthisvictory #victory #foodismedicine #healthandwellness #diet #optimalhealth #sustainableliving #ethicaleating Willis Victory OLUFEMI OLOWOFOYEKU Ronaald Patrik (He/Him/His) Ronda Cobb, BSME Shagun Chaudhary Stefan Xhunga C.J. Wiggins Isaac Mureithi ramis chen Nitu Kumari Ritika Gupta ashish singh Khalsa Toms Astahovskis Stephanie Shaffer 💛💯🧏🏾♀️ James Hawkins Victorita Dutu Teruo Kitamura Silas Green /G\ chimuka simulilika Sreerupa Banerjee Dt.Joyet Thomas Catherine Wong

🌍 New #RWE Study: Prognosis for Multiple Myeloma has Improved, but Prevalence is Increasing The prognosis for patients with multiple myeloma (MM) has improved as treatments have advanced, but the disease remains incurable. The prevalence of the disease is increasing in Finland as the population gets older. This is evident from a recently published nationwide retrospective study based on real-world evidence (RWE). The study reported patient characteristics, incidence rates, survival outcomes, comorbidities, and healthcare resource utilization (HCRU) of all adult Multiple Myeloma (MM) patients diagnosed in Finland between 2000 and 2021. 🌍 The real-world evidence (RWE) study was published by Annals of Hematology in July 2024. The study was sponsored by the #pharmaceutical company Takeda and conducted by Medaffcon in collaboration with several leading experts. The Medical Writer for the study was Medaffcon’s Scientific Advisor, PhD Essi Havula. 🇫🇮 Finland’s Largest Real-World Evidence (RWE) Study on Multiple Myeloma  Multiple myeloma (MM) is an incurable blood cancer that develops from plasma cells in the bone marrow. MM accounts for approximately 10 percent of all hematological cancers and primarily affects elderly individuals.  In Finland, the current median age at diagnosis is 70 years, and the age-standardized incidence rate is 2.5–3 cases per 100,000 people. 📊 “This is the largest RWE study on #multiple #myeloma ever conducted in Finland. This is certainly the strength of this study,” says Medaffcon’s Scientific Advisor, PhD Essi Havula, who was the Medical Writer for the study.  The analysis included a total of 7,070 MM patients diagnosed over 21 years (2000-2021) and their 21,210 age-, gender-, and region-matched controls. Kai Kysenius Anna Anttalainen Iiro Toppila Mariann Lassenius ➡️ Read the whole article here ➡️ https://lnkd.in/dx5iAZJ9 ➡️ The whole study is here ➡️ https://lnkd.in/d2iv6raQ #realworldevidence #nordic

Source: Heliyon This article discusses the use of metabolomics approaches to identify biomarkers for diagnosing and monitoring the progression of Parkinson's disease (PD). The study analyzed the serum metabolome of PD patients and controls using LC-MS/MS and GC-TOF MS techniques. The researchers found that levels of certain metabolites were significantly different in PD patients compared to controls, including cysteine-S-sulfate and N-acetyl tryptophan. Xanthines, including caffeine and its metabolites, were lower in PD patients, suggesting a potential protective role against neuronal damage. The study also identified seven metabolites that yielded a high classification accuracy for PD diagnosis. Furthermore, the levels of cysteine-S-sulfate and LPI 20:4 were found to change with the progression of PD. These findings provide potential biomarkers for PD diagnosis and monitoring and suggest new therapeutic targets for the development of novel treatments.